|
Adenocarcinoma
|
0.090 |
GeneticVariation
|
group |
BEFREE |
In tumor cell lines displaying molecular alterations in potential nintedanib targets, the inhibitor demonstrates direct antiproliferative effects: in the NSCLC cell line NCI-H1703 carrying a PDGFR<i>α</i> amplification (ampl.); the gastric cancer cell line KatoIII and the breast cancer cell line MFM223, both driven by a FGFR2 amplification; AN3CA (endometrial carcinoma) bearing a mutated FGFR2; the acute myeloid leukemia cell lines MOLM-13 and MV-4-11-B with FLT3 mutations; and the NSCLC adenocarcinoma LC-2/ad harboring a CCDC6-RET fusion.
|
29263244 |
2018 |
|
Adenocarcinoma
|
0.090 |
AlteredExpression
|
group |
LHGDN |
Archived tissue from NSCLC (adenocarcinoma and SCC; n = 321) and adjacent bronchial epithelial specimens (n = 426) were analyzed for the immunohistochemical expression of bFGF, FGFR1, and FGFR2, and the findings were correlated with clinicopathologic features of the patients.
|
18829480 |
2008 |
|
Adenocarcinoma of large intestine
|
0.100 |
GeneticVariation
|
disease |
GWASCAT |
Cross-Cancer Genome-Wide Analysis of Lung, Ovary, Breast, Prostate, and Colorectal Cancer Reveals Novel Pleiotropic Associations.
|
27197191 |
2016 |
|
Adenocarcinoma of lung (disorder)
|
0.440 |
GeneticVariation
|
disease |
CLINVAR |
Identifying recurrent mutations in cancer reveals widespread lineage diversity and mutational specificity.
|
26619011 |
2016 |
|
Adenocarcinoma of lung (disorder)
|
0.440 |
GeneticVariation
|
disease |
UNIPROT |
|
|
|
|
Adenocarcinoma of lung (disorder)
|
0.440 |
AlteredExpression
|
disease |
BEFREE |
bFGF, FGFR1, and FGFR2 are frequently overexpressed in SCC and adenocarcinoma of the lung. bFGF signaling pathway activation may be an early phenomenon in the pathogenesis of SCC and thus an attractive novel target for lung cancer chemopreventive and therapeutic strategies.
|
18829480 |
2008 |
|
Adenocarcinoma of lung (disorder)
|
0.440 |
Biomarker
|
disease |
BEFREE |
In summary, a total of nine genes that may play important roles in the development of LUAD were identified, and two (PAK1 and FGFR2) of them can be served as prognostic biomarkers for LUAD patients.
|
30370535 |
2019 |
|
Adenocarcinoma of lung (disorder)
|
0.440 |
GeneticVariation
|
disease |
GWASCAT |
Cross-Cancer Genome-Wide Analysis of Lung, Ovary, Breast, Prostate, and Colorectal Cancer Reveals Novel Pleiotropic Associations.
|
27197191 |
2016 |
|
Adenocarcinoma of lung (disorder)
|
0.440 |
GeneticVariation
|
disease |
BEFREE |
FGFR2 and other FGFR kinase family gene alterations have been found in both lung squamous cell carcinoma and lung adenocarcinoma, although mouse models of FGFR-driven lung cancers have not been reported.
|
25035393 |
2014 |
|
Adenocarcinoma of lung (disorder)
|
0.440 |
Biomarker
|
disease |
BEFREE |
Here the authors propose that TRPA1/FGFR2 interaction is functional in LUAD and show that astrocytes oppose brain metastasis by mediating the downregulation of TRPA1 through exosome-delivered miRNA-142-3p.
|
29038531 |
2017 |
|
Adenocarcinoma, Clear Cell
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
Gene and protein expression of FGFR2 differed significantly between epithelial cells of endometrioma and the epithelial component of clear cell carcinoma.
|
23640291 |
2013 |
|
Adenocarcinoma, Scirrhous
|
0.020 |
GeneticVariation
|
disease |
BEFREE |
Reduction or loss of cadherin and catenins, K-sam gene amplification, and c-met gene amplification are necessary for the development and progression of poorly differentiated or scirrhous carcinoma.
|
7676688 |
1995 |
|
Adenocarcinoma, Scirrhous
|
0.020 |
Biomarker
|
disease |
BEFREE |
Moreover, the K-sam gene is amplified preferentially in poorly differentiated adenocarcinoma of scirrhous carcinoma.
|
8440743 |
1993 |
|
Adenosis of Breast
|
0.010 |
GeneticVariation
|
disease |
BEFREE |
In the MGA/AMGA associated with TNBC lacking TP53 mutations, somatic mutations affecting PI3K pathway-related genes (eg PTEN, PIK3CA, and INPP4B) and tyrosine kinase receptor signalling-related genes (eg ERBB3 and FGFR2) were identified.
|
26806567 |
2016 |
|
Adrenocortical carcinoma
|
0.010 |
Biomarker
|
disease |
BEFREE |
In 18 evaluable patients with FGFR genetic alterations, 3 confirmed partial responses (two intrahepatic cholangiocarcinomas (iCCA) with FGFR2 fusions and one urothelial cancer with FGFR2 and FGF19 amplification) and two durable stable disease at ⩾16 weeks with tumour reduction (FGFR2 fusion-positive iCCA and adrenocortical carcinoma with FGFR1 amplification) were observed.
|
28972963 |
2017 |
|
Adult Anaplastic Astrocytoma
|
0.010 |
Biomarker
|
disease |
BEFREE |
The Cox proportional hazards model, adjusted for patient age at surgery, the preoperative Karnofsky Performance Scale score, and the extent of surgical resection revealed that LOH on marker D10S209 near the FGFR2 and DMBT1 genes was significantly associated with shorter survival in patients with AA.
|
11596960 |
2001 |
|
Adult Hodgkin Lymphoma
|
0.010 |
GeneticVariation
|
disease |
BEFREE |
FGFR2 genotype and risk of radiation-associated breast cancer in Hodgkin lymphoma.
|
22144180 |
2012 |
|
Adult Synovial Sarcoma
|
0.010 |
Biomarker
|
disease |
BEFREE |
They also provide the stem cell regulator, FGFR2, as a promising candidate target for future SS therapy.
|
21996728 |
2012 |
|
Age related macular degeneration
|
0.010 |
Biomarker
|
disease |
BEFREE |
Our findings support the hypothesis that there are two different FGFR-1- and FGFR-2-dependent pathways that modulate the role of bFGF in induction of neovascularisation in AMD.
|
16188231 |
2005 |
|
Agenesis
|
0.010 |
GeneticVariation
|
disease |
BEFREE |
In conclusion, tooth agenesis was associated with positive self-reported family history of cancer and with variants in AXIN2, FGF3, FGF10, and FGFR2.
|
23169889 |
2013 |
|
Agenesis of corpus callosum
|
0.100 |
Biomarker
|
disease |
HPO |
|
|
|
|
Alacrima
|
0.100 |
Biomarker
|
disease |
HPO |
|
|
|
|
Ambiguous Genitalia
|
0.010 |
GeneticVariation
|
disease |
BEFREE |
When grown in the absence of cholesterol to stimulate cholesterol biosynthesis, the cells from the ABS patient with ambiguous genitalia but without an FGFR2 mutation accumulated markedly increased levels of lanosterol and dihydrolanosterol.
|
12116245 |
2002 |
|
Amblyopia
|
0.100 |
Biomarker
|
phenotype |
HPO |
|
|
|
|
Ameloblastoma
|
0.020 |
AlteredExpression
|
disease |
BEFREE |
We examined 32 cases of ameloblastoma as well as AM-1 cells (an ameloblastoma cell line) and studied the expression of FGF3, FGF7, FGF10 and their specific receptors, namely, FGF receptor (FGFR) 1 and FGFR2.
|
24002438 |
2013 |